Satralizumab for the prevention of relapse in patients with a neuromyelitis optica spectrum disorder

27 March 2024 - NICE is unable to make a recommendation on the use of satralizumab (Enspryng) for the prevention of ...

Read more →

Daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adults with newly diagnosed systemic light chain amyloidosis

27 March 2024 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) for the treatment of ...

Read more →

Ritlecitinib tosylate for the treatment of people 12 years and over with alopecia areata

27 March 2024 - NICE has published final evidence-based recommendations on the use of ritlecitinib tosylate (Litfulo) for the treatment ...

Read more →

Momelotinib dihydrochloride monohydrate for the treatment of patients with myelofibrosis-related splenomegaly or symptoms

20 March 2024 - NICE has published final evidence-based recommendations on momelotinib dihydrochloride monohydrate (Omjjara) for the treatment of aduklts ...

Read more →

Dupilumab for the treatment of adults with moderate to severe prurigo nodularis

13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of ...

Read more →

Fluocinolone acetonide for the treatment of patients with chronic diabetic macular oedema

13 March 2024 - NICE has published final evidence-based recommendations on the use of fluocinolone acetonide intravitreal implant (Iluvien) for ...

Read more →

Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments

6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of ...

Read more →

NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources

6 March 2024 - NICE has published final draft guidance that does not recommend Enhertu (trastuzumab deruxtecan; Daiichi Sankyo) for treating ...

Read more →

Pembrolizumab in combination with chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma

5 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

New treatment option available today for womb cancer

5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...

Read more →

Etrasimod arginine for the treatment of patients with moderate to severe active ulcerative colitis

27 February 2024 - NICE has published final evidence-based recommendations on the use of etrasimod arginine (Velsipity) for the treatment ...

Read more →

Voxelotor for the treatment of patients with sickle cell disease (draft guidance)

27 February 2024 - NICE has issued further draft guidance on the use of voxelotor following an appeal hearing in ...

Read more →

Tafamidis for the treatment of patients with transthyretin amyloidosis with cardiomyopathy

27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)

22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate. ...

Read more →